On September 7, 2021 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, reported that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021 (Press release, ImmunoPrecise Antibodies, SEP 7, 2021, View Source [SID1234587328]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H.C. Wainwright 22nd Annual Global Investment Conference (Virtual Conference)

Date: September 13-15, 2021

Presentation Day & Time: September 10, 6:00 PM (EDT)

Location: View Source

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

On September 7, 2021 Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, reported the company will participate in the following two virtual investment conferences taking place in September 2021 (Press release, Istari Oncology, SEP 7, 2021, View Source [SID1234587327]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Morgan Stanley’s 19th Annual Global Healthcare Conference
Speaker: Executive leadership, Istari Oncology
Session Date/Time: Tuesday, September 14, 2021, from 5:00 – 5:30 p.m. EDT
Format: Fireside chat
Registration: Interested parties can attend the live webcast of Istari’s fireside chat here. The webcast will also be archived on www.istarioncology.com.

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Speaker: Garrett Nichols, CMO, Istari Oncology
Session Date/Time: Available on-demand from September 13-15, 2021, beginning at 7:00 a.m. EDT
Format: Company presentation
Registration: Institutional investors can register for the conference and view Istari’s on-demand presentation here.

On September 7, 2021 Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, reported that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13 – 15, 2021 (Press release, Applied DNA Sciences, SEP 7, 2021, View Source [SID1234587326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on September 13, 2021, and can be accessed through the Investors Relations section of Applied DNA website at www.adnas.com or directly through the webcast link. An archived replay of the webcast will be available on the Company’s website after the conference.

On September 7, 2021 TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021 (Press release, Tracon Pharmaceuticals, SEP 7, 2021, View Source [SID1234587325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

On September 7, 2021 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported that Vincerx’s management team will participate in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference, to be held September 9-10, 2021 (Press release, Vincerx Pharma, SEP 7, 2021, View Source [SID1234587324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vincerx Fireside Chat Details

Date: Thursday, September 9, 2021

Time: 4:40 PM Eastern Time

Webcast: View Source
The presentation will be webcast live and archived for 90 days in the Investors section of the Company’s website.